A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations

BACKGROUND: The CCR5 antagonist maraviroc (MVC) inhibits human immunodeficiency virus type 1 (HIV-1) entry by altering the CCR5 extracellular loops (ECL), such that the gp120 envelope glycoproteins (Env) no longer recognize CCR5. The mechanisms of HIV-1 resistance to MVC, the only CCR5 antagonist li...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Roche, Michael, Salimi, Hamid, Duncan, Renee, Wilkinson, Brendan L, Chikere, Kelechi, Moore, Miranda S, Webb, Nicholas E, Zappi, Helena, Sterjovski, Jasminka, Flynn, Jacqueline K, Ellett, Anne, Gray, Lachlan R, Lee, Benhur, Jubb, Becky, Westby, Mike, Ramsland, Paul A, Lewin, Sharon R, Payne, Richard J, Churchill, Melissa J, Gorry, Paul R
Médium: Artigo
Jazyk:Inglês
Vydáno: BioMed Central 2013
Témata:
Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3648390/
https://ncbi.nlm.nih.gov/pubmed/23602046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1742-4690-10-43
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky